Docket No.

275596US96X PCT

# IAP7 Rec'o POPTO 06 JUN 2006PCT #2

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Haruo SUGIYAMA, et al.

SERIAL NO:

10/517,600

GAU:

FILED:

December 13, 2004

**EXAMINER:** 

FOR:

HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

#### **DEPOSIT ACCOUNT**

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

James J. Kelly, Ph.D.

Registration No. 41,504

Surinder Sachar

Registration No. 34,423

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Form PTO 1449 (Modified)		U.S. DEPARTMENT (	OF COMMERCE	ATTY DOCKET NO.		SERIAL NO.			
		PATENT AND TRADEMARK OFFICE		275596US96X PCT	10/517,600				
OIPE				APPLICANT					
LIST OF REFERENCES CITES BY APPLICANT				Haruo SUGIYAMA, et al.					
( JUN 0 6 2006 J			FILING DATE		GROUP				
			December 13, 2004						
	1	h		U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		NUMBER	DATE	NAME	CLASS	SUB FILING DATE CLASS IF APPROPRIATE			
	AA								
	AB								
	AC								
	AD								
	AE								
	AF								
	AG				ļ				
	АН								
	Al								
	AJ								
	AK								
	AL								
	AM			•					
	AN				<u> </u>				
			FC	REIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSL YES		LATION NO	
	AO								
ſi .	AP								
	AQ								
	AR					<u> </u>			
	AS								
	AT					ļ			
	AU					<u> </u>	_		
	AV								
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)									
	OKA, Yoshihiro et al., "Human Cytotoxic T-lymphocyte responses specific for peptides of the Wild-type Wilms' tumor gene (WT1) Product", Immunogenetics, Vol. 51, No. 2, Pages 99-107, 2000.								
	AX								
	AY								
	AZ				Additional References sheet(s) attached				
Examiner					Date Co	Date Considered			
*Examiner: li	nitial if i	reference is considered, ot considered. Include c	whether or no	ot citation is in conformance with MPEP $\epsilon$ m with next communication to applicant.	609; Draw I	ine through	n citation	if not in	

U.S. PCT Application Serial No: 10/517,600

Filed: December 13, 2004 Haruo SUGIYAMA, et al. Decket No. 275596 US

Haruo Si P E Dacket I

## STATEMENT OF RELEVANCY

- 1) References have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References AW has been cited in the corresponding Supplementary European Search Report. A copy of this reference is being submitted herewith.
- 3) References are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.